LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY

被引：1

作者：

Johnston, D.

Banerji, A.

Riedl, M.

Zuraw, B.

Lumry, W.

Bernstein, J.

Li, H.

Lu, P.

Hao, J.

Gower, R.

机构：

来源：

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期

关键词：

D O I：

10.1016/j.anai.2018.09.114

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

P166

引用

页码：S36 / S36

页数：1

共 50 条

[21] Lanadelumab prophylaxis reduces breakthrough hereditary angioedema attacks and the need for rescue medication: Exploratory findings from the phase 3 HELP study [J].

Cicardi, M. ;

Maurer, M. ;

Longhurst, H. J. ;

Johnston, D. T. ;

Li, H. H. ;

Nurse, C. ;

Lu, P. ;

Busse, P. J. .

ALLERGY, 2019, 74 :212-212

[22] Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study [J].

Maurer, Marcus ;

Lumry, William R. ;

Li, H. Henry ;

Aygoren-Pursun, Emel ;

Busse, Paula J. ;

Jacobs, Joshua ;

Nurse, Christina ;

Ahmed, Mariam A. ;

Watt, Maureen ;

Yu, Ming .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (01) :201-211.e6

[23] IMMUNOGENICITY ASSESSMENT OF EFANESOCTOCOG ALFA: RESULTS FROM THE PHASE 3 XTEND-1 STUDY [J].

Koenigs, C. ;

Matino, D. ;

Young, G. ;

Dumont, J. ;

Seth Chhabra, E. ;

Kramer, D. ;

Santagostino, E. ;

Yarramaneni, A. ;

Peyvandi, F. .

HAEMOPHILIA, 2023, 29 :12-12

[24] Integrated Phase 3 Immunogenicity Results for Albiglutide [J].

Johnson, Susan ;

Nauck, Michael A. ;

Zhi, Hui ;

Weston, Cynthia ;

Russo, Carlo ;

Holland, M. Claire .

DIABETES, 2014, 63 :A427-A427

[25] Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study [J].

Hide, Michihiro ;

Ohsawa, Isao ;

Nurse, Christina ;

Yu, Ming .

JOURNAL OF DERMATOLOGY, 2023, 50 (11) :1381-1391

[26] Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study [J].

Johnston, Douglas T. ;

Busse, Paula J. ;

Riedl, Marc A. ;

Maurer, Marcus ;

Anderson, John ;

Nurse, Christina ;

Inhaber, Neil ;

Yu, Ming ;

Banerji, Aleena .

CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (10) :1391-1395

[27] Lanadelumab safety and efficacy in hereditary angioedema after switching from prior long-term prophylaxis: analysis from the HELP OLE study [J].

Mansour, E. ;

Bernstein, J. ;

Riedl, M. ;

Kiani, S. ;

Aygoren-Pursun, E. ;

Choudhry, Z. ;

Jain, S. ;

Nurse, C. ;

Yegin, A. ;

Banerji, A. .

ALLERGY, 2023, 78 :12-12

[28] Consistent Lanadelumab Treatment Effect In Patients With Hereditary Angioedema (HAE) Regardless Of Baseline Attack Frequency In The Phase 3 HELP Study [J].

Riedl, Marc A. ;

Tachdjian, Raffi ;

Schranz, Jennifer ;

Nurse, Christina ;

Bernstein, Jonathan A. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) :AB47-AB47

[29] Advancing AIDSVAX™ to phase 3.: Safety, immunogenicity, and plans for phase 3 [J].

Francis, DP ;

Gregory, T ;

McElrath, MJ ;

Belshe, RB ;

Gorse, GJ ;

Migasena, S ;

Kitayaporn, D ;

Pitisuttitham, P ;

Matthews, T ;

Schwartz, DH ;

Berman, PW .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 :S325-S331

[30] EFFICACY AND SAFETY OF ADALIMUMAB IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS: RESULTS FROM A PHASE 3 STUDY [J].

Mease, P. ;

Sieper, J. ;

van den Bosch, F. ;

Rahman, P. ;

Obermeyer, K. ;

Pangan, A. L. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 :250-250

← 1 2 3 4 5 →